This paper sought to describe and discuss the new guidelines for the treatment of hyperglycemia in patients with Type 2 diabetes, published in 2020 by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Besides lifestyle measures, metformin remains the first-line treatment. Additional antihyperglycemic agents are now selected depending of a past history of cardiovascular or renal diseases. Antidiabetic agents with proven cardiac and renal protection should be privileged, particularly in secondary prevention. These recommendations define a structured strategy, which must be implemented in each country, according to internal rules.
Key Words
Treatment, hyperglycemia, ADA-EASD, cardiovascular complications, nephropathy
What does this article bring up for us?
This article discusses the new therapeutic guidelines of hyperglycemia in type 2 diabetes published in 2020.